THE AGA KHAN UNIVERSITY

Fellowship in Oncopathology

Background

The Aga Khan University (AKU) is a private, not-for-profit, international University first established in 1983, with 11 teaching sites in eight countries. Aga Khan University Hospital, Nairobi (AKUHN) is a premier teaching and referral hospital offering training and tertiary care in an array of disciplines including pathology.

The AKUHN launched a 2-year sub-specialty fellowship training in Oncopathology on March 1, 2023. The program is organized to provide training and supervised experience at a sufficient level for the fellow to acquire the competency of a specialist in the various fields of Oncopathology, including Surgical Oncopathology, Immunohistochemistry, Hematopathology and Blood transfusion, Flowcytometry and Molecular Oncopathology. In addition, the fellow will gain expertise in cancer research and laboratory management.

Goals and Objectives

The primary goal of the program is to provide the trainee with a broad understanding of clinical and academic principles in the practice of Oncopathology. Fellows will have direct hands-on experience in all aspects of their training, guided by our competency-based curriculum. Fellows enjoy the diversity of a tertiary care teaching hospital, with the facilities, amenities and support of an internationally accredited medical laboratory in the region.

The Program intends to produce highly skilled sub-specialists capable of providing excellent service for the country and the region and conduct independent research to expand the body of knowledge in the field of Oncopathology.

Roles and responsibilities:

The successful candidate will have dual reporting to the Fellowship Program Director and Chair in Department of Pathology and will be expected to perform the following duties.

1. Daily sign out of previewed histology and cytology cases with the assigned consultant
2. Ordering and interpretation of immunohistochemistry with assigned consultant
3. Perform frozen sections under supervision.
4. Teach and supervise residents on grossing techniques and performing fine needle aspirates
5. Daily sign out of peripheral blood films, bone marrow aspirates and trephines with assigned consultant
6. Perform bone marrow aspirates under supervision
7. Interpret flow cytometry under supervision
8. Order and interpret oncology molecular tests under supervision

9. Direct under supervision the preparation and safe use of blood and blood products and marrow or stem cells for transplantation
10. Present in multidisciplinary tumor boards
11. Present in academic half days and journal clubs
12. Participate in the department's quality assurance program
13. Conduct research and submit manuscript(s) for publication

Desirable Personal Attributes

- Demonstrated competency and dexterity with all equipment utilized in a laboratory
- environment
- Good communication skills
- A team player
- A keen learner with good study habits
- Demonstrated honesty, integrity and compassion
- principles appropriately
- Seeks and accepts advice, and adheres to deadlines
- Punctual and respects commitments made

Eligibility

- Hold a Bachelor of Medicine and Bachelor of Surgery (MBChB) or equivalent.
- Hold a Master of Medicine degree (MMed) or equivalent in Anatomic Pathology or General Pathology.
- Registered/eligible for registration by the Kenya Medical Practitioners and Dentists Council.
- Candidates from the public sector under institutional sponsorship should be willing to sign a bonding agreement requiring that they return to the public sector upon completion of training.

How to Apply:

Applications should include a cover letter, statement of motivation, detailed current Curriculum Vitae including names, postal and e-mail addresses, telephone numbers of two professional referees and testimonials. Short-listed candidates will be contacted and invited to interview. The application should be sent by email to:

The Program Director, Oncopathology
Department of Pathology
Aga Khan University
Email: mc.ea@aku.edu

The closing date for applications is June 30, 2024.